상세 보기
자료 필터
자료유형
발행연도
2005 ~ 2038
2005 2038
키워드
언어
전체 147건 중 21번부터 30번까지의 결과를 표시합니다.
2025
Article
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
- Im, S. A. ;
- Park, K. ;
- Koh, J. ;
- Park, C. ;
- Jung, K. H. ;
- ... Park, Kyong Hwa ;
- ... Park, In Hae ;
- 외 29명
- 2025-10
- ESMO Open
- BMJ PUBLISHING GROUP
Article
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
- Lee, Jieun ;
- Ahn, Hee-kyung ;
- Lee, Kyung-hun ;
- Jung, Kyung-hae ;
- Park, Yeonhee ;
- ... Park, KyongHwa ;
- ... Park, In Hae ;
- 외 23명
- 2025-08
- BMC Cancer
- BioMed Central
Article
Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)
- Lee, Jieun ;
- Lee, Dae-Won ;
- Kim, Min Hwan ;
- Kim, Jee Hung ;
- Kim, Ju Won ;
- ... Park, In Hae ;
- 외 19명
- 2025-08
- Breast
- Churchill Livingstone
Article
Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)
- Ahn, Hee Kyung ;
- Kim, Jee Hung ;
- Koh, Su-Jin ;
- Sohn, Joohyuk ;
- Kang, Myoung Joo ;
- ... Park, In Hae ;
- ... Park, Kyong Hwa ;
- 외 15명
- 2025-07
- The Lancet Regional Health. Western Pacific
- Elsevier
Conference
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13).
- Kim, Ju Won ;
- Park, Yeon Hee ;
- Ahn, Hee Kyung ;
- Bae, Jihong ;
- Park, Suk-Young ;
- ... Park, In Hae ;
- ... Choi, Jung Yoon ;
- ... Park, KyongHwa ;
- 외 7명
- 2025-06-01
- 미국
Conference
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
- Sohn, Joohyuk ;
- Lim, Seungtaek ;
- Jeong, Jae Ho ;
- Lee, Kyung-Hun ;
- Lee, Keun Seok ;
- ... Park, In Hae ;
- ... Park, Kyonghwa ;
- 외 13명
- 2025-06-01
- 미국
Article
Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial
- Lee, Kyoungmin ;
- Lee, Kyung-Hun ;
- Kim, Dong-Wan ;
- Yoon, Jeesun ;
- Choi, Yoon Ji ;
- ... Lee, Soohyeon ;
- ... Kim, Ju Won ;
- ... Park, Kyong Hwa ;
- ... Kang, Eun Joo ;
- ... Park, In Hae ;
- 외 11명
- 2025-04
- Cancer Communications
- Wiley
Article
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
- Ahn, Hee Kyung ;
- Kim, Ji-Yeon ;
- Lee, Kyung-Hun ;
- Kim, Gun Min ;
- Kang, Seok Yun ;
- ... Park, In Hae ;
- 외 16명
- 2025-03
- The Lancet Oncology
- The Lancet Publishing Group